Study questions whether hormone therapy more deleterious than chemotherapy in breast cancer cases
In postmenopausal women with breast cancer, hormone therapy would cause more side effects than chemotherapy. In the long term, the comfort of everyday life would be altered.
Hormone therapy effectively prevents the risk of relapse of hormone-dependent breast cancer. But this therapeutic strategy would durably impact the quality of life of menopausal women.
Scientists followed 4,262 women with breast cancer. Their quality of life was assessed at diagnosis, then at 1 and 2 years. About 75 to 80% of them were then placed on hormone therapy for a minimum of 5 years.
Overall, quality of life has deteriorated in all patients. But the sequelae have increased in women on hormone therapy. Precisely, two years after the diagnosis, “hormone therapy (…) has a longer and more deleterious impact on the quality of life, especially for postmenopausal women”.
Conversely, “the impact of chemotherapy is more important on the quality of life of premenopausal women, particularly on the deterioration of cognitive functions”.
Prevention is needed while international recommendations are based on a prescription of hormone therapy for 5 to 10 years. Objective, identify risk profiles to “offer them a management of the most impacting symptoms, especially those related to menopause, musculoskeletal pain, depression, severe fatigue, or cognitive dysfunction, and include supportive care such as exercise and cognitive-behavioral therapies. “